GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Price-to-Owner-Earnings

Lexeo Therapeutics (Lexeo Therapeutics) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-09), Lexeo Therapeutics's share price is $17.25. Lexeo Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lexeo Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


LXEO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Lexeo Therapeutics's share price is $17.25. Lexeo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.64. Therefore, Lexeo Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-09), Lexeo Therapeutics's share price is $17.25. Lexeo Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.62. Therefore, Lexeo Therapeutics's PE Ratio without NRI for today is At Loss.


Lexeo Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Lexeo Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Price-to-Owner-Earnings Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexeo Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Lexeo Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexeo Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's Price-to-Owner-Earnings falls into.



Lexeo Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lexeo Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=17.25/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexeo Therapeutics  (NAS:LXEO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lexeo Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lexeo Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexeo Therapeutics (Lexeo Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Richard Nolan Townsend director, officer: Chief Executive Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson officer: Chief Legal and Admin. Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paul Mccormac officer: Chief Technical Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler officer: Chief Scientific Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Paula H Cholmondeley director 221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Reinaldo M Diaz director C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830

Lexeo Therapeutics (Lexeo Therapeutics) Headlines